M. Arock

KIRA6 is an effective and versatile mast cell inhibitor of IgE-mediated activation

This study identifies KIRA6 as a dual inhibitor of LYN and FYN that suppresses IgE-mediated mast cell activation and inflammation.

SR-BI regulates the synergistic mast cell response by modulating the plasma membrane-associated cholesterol pool

This paper identifies SR-BI as a regulator of mast cell activation by modulating plasma membrane cholesterol, affecting synergistic responses to multiple stimuli.

Involvement of an IgE/Mast cell/B cell amplification loop in abdominal aortic aneurysm progression

This study identifies an IgE/mast cell/B cell amplification loop that drives abdominal aortic aneurysm progression by promoting IL-4 production and subclinical fissure healing impairment.

Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia

The paper shows that combining low-dose Ponatinib and Trametinib can overcome Imatinib resistance in mast cell leukemia by inhibiting paradoxical MAPK pathway activation.

Single-cell analysis reveals the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis

This study identifies the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis, showing it is present in nearly all mast cells and spans the hematopoietic lineage.

Divergent effects of acute and prolonged interleukin 33 exposure onmast cell IgE-mediated functions

This study examines how acute versus prolonged IL-33 exposure affects mast cell mediator synthesis and IgE-mediated activation, finding divergent effects on cytokine release and IgE responses.